Sciensano does not recommend using hydroxychloroquine for Covid-19 treatment – Health

0
1


Sciensano yesterday amended its guidelines for the treatment of hospitalized corona patients. The use of the malaria drug hydroxychloroquine is now strongly discouraged.

The research institution is based on the recent observational findings about the use of hydroxychloroquine for corona patients. It consistently shows that it offers no benefits, and may even have harmful effects. “It has been decided to no longer recommend the off-label use (use for an indication or patient group for which the medicine was not registered, ed.) For covid-19 in Belgium”, the amended guideline states.

For Sciensano, use can only be performed in ongoing clinically registered tests after the risks and benefits associated with the study have been carefully reassessed. According to the scientific institute, the federal drug agency FAMHP registered in eight cases in Belgium side effects that were probably caused by the use of hydroxychloroquine for the treatment of covid-19. Three cases involved cardiac side effects that were not fatal.

Sciensano also states that he is currently analyzing data from Belgian hospitals on the treatments since the start of the corona epidemic, with a focus on the impact of hydroxychloroquine.

The FAMHP repeated Monday its warning about the risk of arrhythmias associated with the use of hydroxychloroquine. It did so after a study published in the British medical journal The Lancet last Friday, which revealed the cardiovascular side effects of the drug. As a result of the same study, the World Health Organization (WHO) decided to discontinue clinical trials with hydroxycholoroquine.

The research institution is based on the recent observational findings about the use of hydroxychloroquine for corona patients. It consistently shows that it offers no benefits, and may even have harmful effects. “It has been decided to no longer recommend the off-label use (use for an indication or patient group for which the medicine was not registered, ed.) For covid-19 in Belgium”, the amended guideline states. for Sciensano only in ongoing clinically registered tests, after the risks and benefits associated with the study have been carefully reassessed. According to the scientific institute, the federal drug agency FAMHP registered in eight cases in Belgium side effects that were probably caused by the use of hydroxychloroquine for the treatment of covid-19. In three cases, these were side effects to the heart, which were not fatal, however, Sciensano also states that he is currently analyzing the data from the Belgian hospitals about the treatments since the start of the corona epidemic, with a focus on the impact of hydroxychloroquine. The FAMHP repeated Monday its warning about the risk of arrhythmias associated with the use of hydroxychloroquine. It did so after a study published in the British medical journal The Lancet last Friday, which revealed the cardiovascular side effects of the drug. As a result of the same study, the World Health Organization (WHO) decided to discontinue clinical trials with hydroxycholoroquine.

LEAVE A REPLY

Please enter your comment!
Please enter your name here